Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4697-4705

  Gupte, Anisha A ^a   Sabek, Omaima M ^b   Fraga, Daniel ^b   Minze, Laurie J ^a   Nishimoto, Satoru K ^c   Liu, Joey Z ^a,d   Afshar, Solmaz ^b   Gaber, Lillian ^b   Lyon, Christopher J ^a   Gaber, A Osama ^b   Hsueh, Willa A ^a,d  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCALCIN;

ANIMAL; COMPLICATION; DISEASE MODEL; DRUG SCREENING; FATTY LIVER; FIBROSIS; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; FIBROSIS; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MICE; OSTEOCALCIN;

EID: 84914141377     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1430     Document Type: Article

References (38)

1. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31:219-230.
2. Mainous AG 3rd, Baker R, Koopman RJ, et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia. 2007;50:934-940.
3. Tilg H, Moschen AR. Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov. 2014;9:687-696.
4. Aller R, Castrillon JL, de Luis DA, et al. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann Hepatol. 2011;10:50-55.
5. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50:568-575.
6. Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and β-cell function in overweight adults. J Clin Endocrinol Metab. 2013;98:E1173-E1180.
7. Wang Q, Zhang B, Xu Y, Xu H, Zhang N. The relationship between serum osteocalcin concentration and glucose metabolism in patients with type 2 diabetes mellitus. Int J Endocrinol. 2013;2013:842598.
8. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122:4172-4189.
9. Pietschmann P, Resch H, Müller C, Woloszczuk W, Willvonseder R. Decreased serum osteocalcin levels in patients with liver cirrhosis. Bone Miner. 1990;8:103-108.
10. Liu JJ, Chen YY, Mo ZN, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China. Int J Mol Sci. 2013;14:19782-19791.
11. Fernández-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int. 2010; 21:2101-2107.
12. Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest. 2011;71:631-636.
13. Gupte AA, Liu JZ, Ren Y, et al. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology. 2010;52:2001-2011.
14. Collins AR, Lyon CJ, Xia X, et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res. 2009;104:e42-e54.
15. Gupte AA, Minze LJ, Reyes M, et al. High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance. Endocrinology. 2013;154:2650-2662.
16. Nishimoto SK, Price PA. Proof that the γ-carboxyglutamic acid-containing bone protein is synthesized in calf bone. Comparative synthesis rate and effect of coumadin on synthesis. J Biol Chem. 1979;254:437-441.
17. Nishimoto SK, Price PA. The vitamin K-dependent bone protein is accumulated within cultured osteosarcoma cells in the presence of the vitamin K antagonist warfarin. J Biol Chem. 1985;260:2832-2836.
18. Nishimoto SK, Araki N, Robinson FD, Waite JH. Discovery of bone γ-carboxyglutamic acid protein in mineralized scales. The abundance and structure of Lepomis macrochirus bone γ-carboxyglutamic acid protein. J Biol Chem. 1992;267:11600-11605.
19. Nishimoto SK. A colorimetric assay specific for γ-carboxyglutamic acid-containing proteins: its utility in protein purification procedures. Anal Biochem. 1990;186:273-279.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
21. Hill HS, Grams J, Walton RG, Liu J, Moellering DR, Garvey WT. Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. Horm Metab Res. 2014;46:341-347.
22. Zhou B, Li H, Liu J, et al. Intermittent injections of osteocalcin reverse autophagic dysfunction and endoplasmic reticulum stress resulting from diet-induced obesity in the vascular tissue via the NFκB-p65-dependent mechanism. Cell Cycle. 2013;12:1901-1913.
23. Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115.
24. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(suppl 1):68-76.
25. Sheedfar F, Sung MM, Aparicio-Vergara M, et al. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease. Aging (Albany NY). 2014;6:281-295.
26. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219.
27. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371-379.
28. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
29. Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? Aging Cell. 2013;12:950-954.
30. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351.
31. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-358.
32. Bertola A, Deveaux V, Bonnafous S, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes. 2009;58:125-133.
33. Yilmaz Y, Ozturk O, Alahdab YO, et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2013;45:58-62.
34. Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117:2877-2888.
35. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318-1331.
36. Deng T, Cui J, Lyon CJ, et al. Inflammasomes and obesity. Obesity, Inflammation and Cancer Springer Science+Business Media New York. 2013;2013:25-60.
37. Deng T, Lyon CJ, Minze LJ, et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 2013;17:411-422.
38. Zhou B, Li H, Xu L, Zang W, Wu S, Sun H. Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway. Endocrinology. 2013;154:1055-1068.